About Claris Ventures
Claris Ventures is a venture capital firm founded in 2019. It is primarily based out of Italy. As of Dec 2025, Claris Ventures is an active investor, having invested in 11 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in Italy based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Seed round of Haptena A lot of funds co-invest with Claris Ventures, with names like 3B Future Health Fund sharing a substantial percentage of its portfolio. Claris Ventures has team of 8 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 1 more
Claris Ventures' List of Top Investments
Claris Ventures has a portfolio of 11 companies. Their most notable investments are in IAMA Therapeutics and Repron Therapeutics.Their portfolio spans across Italy, United Kingdom and United States. They have invested in Life Sciences, Enterprise Applications, High Tech and 2 other sectors, across stages such as Series A, Seed and 1 more. Here is the list of top investments by Claris Ventures:
Developer of therapeutics for metabolic, oncology, and liver disease. The company is developing anti-miRNA compounds based on locked nucleic acid technology to restore a healthy homeostat and regulate lipid metabolism to treat metabolic disorders, including NASH, obesity, and cancer.
Key facts about Resalis Therapeutics
Developer of treatments for rare pulmonary diseases. The company is developing drugs that target the PI3K signaling pathway which includes KIT2014 and KITCL27, focusing on cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF).
Key facts about Kither biotech
- Founded Year: 2010
- Location: Sant Ambrogio di Torino (Italy)
- Stage: Series B
- Total Funding till date: $26.6M
- Employee Count: 20 as on Sep 30, 2026
- Investors: 3B Future Health Fund, Elysia Capital and 11 Others
- Latest Funding Round: Series B, Mar 16, 2022, $*****
- Highlight: Editors' Pick
AI-powered platform for drug discovery. The company's approach, named "Pharmacological protein Inactivation by Folding Intermediates Targeting" (PPI-FIT), allows them to identify and develop small molecules acting on targets involved in different types of diseases. It's pipeline currently focuses on Cyclin D1 and KRAS as the main targets for oncology and inflammatory diseases.
Key facts about Sibylla Biotech
- Founded Year: 2017
- Location: Trento (Italy)
- Stage: Series A
- Total Funding till date: $25.2M
- Employee Count: 41 as on Aug 31, 2026
- Investors: Indaco Venture Partners, 3B Future Health Fund and 8 Others
- Latest Funding Round: Series A, Oct 04, 2022, $*****
- Highlight: Editors' Pick
4. NeoPhore
Developer of small molecule therapies to treat cancer. The therapies target genetic mechanisms to create neoantigen which stimulates the immune system. The company engages in the inactivation of the DNA mismatch repair (MMR) gene which promotes neoantigen creation and provides immunity against numerous cancers
Key facts about NeoPhore
- Founded Year: 2017
- Location: Cambridge (United Kingdom)
- Stage: Series B
- Total Funding till date: $44.6M
- Employee Count: 10 as on Mar 31, 2025
- Investors: Bristol-Myers Squibb, 3B Future Health Fund and 11 Others
- Latest Funding Round: Series B, Feb 01, 2024, $*****
- Highlight: Editors' Pick
Developer of therapeutics for the treatment of neurological diseases. The company's platform is to identify and advance diverse classes of small molecules to selectively inhibit the sodium-potassium chloride cotransporter (NKCC1) and other therapeutic targets relevant to treating central nervous system disorders including primary and secondary autism, epilepsy, and movement disorders.
Key facts about IAMA Therapeutics
- Founded Year: 2021
- Location: Genoa (Italy)
- Stage: Series B
- Total Funding till date: $25.9M
- Employee Count: 9 as on Aug 31, 2026
- Investors: Indaco Venture Partners, CDP Venture Capital and 2 Others
- Latest Funding Round: Series B, Apr 17, 2025, $*****
- Highlight: Editors' Pick
Claris Ventures' Year-on-Year Investment Trends
Claris Ventures has invested in 11 companies over the last 5 years, with an average of 2 new investments annually in the last 5 years. In 2025, it made 3 investments. Its most recent first time investment was in Haptena and most recent follow-on round was in IAMA Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 2 | 1 | 3 |
2024 | 0 | 2 | 2 |
2023 | 3 | 1 | 4 |
2022 | 4 | 0 | 4 |
2021 | 1 | 0 | 1 |
Claris Ventures' Investments by Stage
Claris Ventures has made 5 investments in Series A stage with an average round size of $10.5M, 3 investments in Seed stage with an average round size of $5.45M and 2 investments in Series B stage with an average round size of $20.7M.Stage of entry | No. of Investments |
|---|---|
Series A | 5 |
Seed | 3 |
Series B | 2 |
Note: We have considered here, only first round of investments
Claris Ventures' Investments by Sector
Claris Ventures has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, Healthcare, High Tech and Artificial Intelligence - Industry Applications. Notably, it has invested in 7 Enterprise (B2B) companies, 7 Tech companies, 2 Software companies and 1 company focusing on AI-Native.Sector | No. of Investments |
|---|---|
Life Sciences | 8 |
Enterprise Applications | 2 |
Healthcare | 2 |
High Tech | 2 |
Artificial Intelligence - Industry Applications | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Claris Ventures' Investments by Geography
Claris Ventures has made most investments in Italy (9), followed by United Kingdom where it has made 1 investment.Country | No. of Investments |
|---|---|
Italy | 9 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
Claris Ventures' recent investments
Claris Ventures has not made any investment in 2026 so far.Here are the most recent investments by Claris Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Dec 16, 2025 | Italy | Seed | 6924 | - | |
May 28, 2025 | Italy | Series A | 3999 | - | |
Apr 17, 2025 | Italy | Series B | 5724 | ||
Feb 01, 2024 | United Kingdom | Series B | 5049 | ||
Jan 04, 2024 | Italy | Series A | 6023 | [+1] |
Team profile of Claris Ventures
Claris Ventures has a team of 8 members including 3 Partners located in Italy and Switzerland. Claris Ventures' team does not sit on the board of any company as of now.Here is a list of all team members in Claris Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Turin | - | ||
Partner | Basel | - | ||
Partner | Collegno | - | - |
Co-investors of Claris Ventures
Over the past 5 years, 38 investors have co-invested in Claris Ventures's portfolio companies. This includes funds and angels.
- Invested before Claris Ventures: CDP Venture Capital, Club degli Investitori and 9 others have invested in rounds before Claris Ventures. There is 1 company where CDP Venture Capital has invested before Claris Ventures and 1 company where Club degli Investitori has invested before Claris Ventures.
- Top Co-investors of Claris Ventures: 18 investors entered a company along with Claris Ventures. These include investors like 3B Future Health Fund (3 companies).
- Invested after Claris Ventures: A total of 9 investors have invested in Claris Ventures's portfolio after their investments. Top Investors include Sanofi (1 company), Sunstone (1 company) and Theinvestorsclub (1 company).
Recent News related to Claris Ventures
•
Haptena Therapeutics Secures €3 Million Funding from Claris Ventures for KRAS-Mutated Tumor TherapiesBorn2Invest•Jan 06, 2026•Claris Ventures
•
•
Claris Ventures Launches Claris Biotech II Fund, Secures Initial FundingBeBeez•Apr 23, 2025•Claris Ventures
•
Turin-based Resalis Therapeutics cashes in on new round from multinational pharmaceutical company SanofiBeBeez•Nov 05, 2024•Resalis Therapeutics, Sanofi, Claris Ventures, Club degli Investitori and 2 others
•
Claris Ventures and Exor Ventures alleviate themselves to develop innovative drugs in Italy.Leverbio was bornBeBeez•May 16, 2024•Leverbio, Exor, Claris Ventures
•
Evotec & Claris Ventures Partner to Accelerate Programs into the Clinical StageContract Pharma•Mar 06, 2024•Evotec, Claris Ventures
•
NeoPhore adds $12.2m in Series B extension for immuno-oncology pipelinePharmaceutical Technology•Feb 01, 2024•NeoPhore, Sixth Element Capital, Claris Ventures, Astellas Venture Management and 5 others
•
miRNA specialist Resalis Therapeutics Srl raises €10m in Series A financingEuropean Biotechnology•Jan 05, 2024•Resalis Therapeutics, Sunstone, Claris Ventures
•
ALKemistBio, investment round of 6.9 million eurosTeleborsa•Dec 21, 2023•Claris Ventures, Club degli Investitori, Simon Fiduciaria, Italian Angels for Growth and 3 others
•
Repron Therapeutics raises €2m in round led by Claris VenturesBeBeez•Jun 14, 2023•CNR, Repron Therapeutics, Claris Ventures, San Raffaele Hospital
